No abstract

No abstract

Objective: To determine the frequency of molar pregnancy in abortion cases diagnosed by histopathology specimens. Study Design: A cross-sectional study. Place and Duration of the Study: Department of Obstetrics & Gynecology, Nishtar Medical University Hospital, Multan from March 2020 to November 2020. Material and Methods: A total of 243 pregnant women with singleton pregnancy aged 18 to 40 years with gestational age below 22 weeks presenting with abortion and admitted to labor ward of Nishtar Medical University Hospital, Multan were included. Both suction and sharp curettage specimens were obtained and submitted to the institutional pathology department for histopathological examination. Presence of molar pregnancy was noted. Results: In a total of 243 women, mean age of the women was 29.6±4.5 years while 112(46.1%) women were aged between 26 to 30 years. Mean gestational age was 16.9±3.4 weeks whereas 39(16.0%) women were in their 1st trimester of pregnancy and 204(84.0%) in 2nd trimester of pregnancy. A total of 142(58.4%) women belonged to rural areas of residence. There were 58 (23.9%) women who were illiterate. Molar pregnancy was noted in 5(2.1%) patients, out of which, there were 2 cases of complete mole and 3 cases of partial mole. Conclusion: Frequency of molar pregnancy in this study was 2.1% including 2 cases of complete and 3 cases of partial mole. Keywords: Hydatidiform mole, gestational trophoblastic disease, molar pregnancy

COVID-19 pandemic impacted human health and the global economy. There is a huge uncertainty about the management of this disease, many drugs including some older drugs are being tested for efficacy and safety including the medicines from the complementary and alternative system. The Central Council for Research in Ayurvedic Sciences, India's apex body for Ayurvedic research and development under the Ministry of AYUSH, has developed a poly-herbal drug called AYUSH 64 for covid 19 which is considered to be having role in the COVID-19. This study was designed with the aim of assessing the efficacy and safety of AYUSH 64 in mild covid-19 patients as add on therapy with standard treatment. It was an open labelled, comparative, parallel group, Randomized controlled clinical trial. Total 60 stage I (mild) COVID 19 positive subjects were recruited, 30 were assigned to AYUSH 64 as an add on therapy along with the standard treatment and 30 were assigned to standard treatment as per the protocols. RT-PCR test was done as per government guidelines and protocol. Along with the RT-PCR clinical laboratory tests were also performed at screening as well as on the discharge as per the study schedule. Absolute events of negative RT-PCR at day 5 were more in the AYUSH 64 group as compared to control group but it was not statistically significant (70% Vs 54%, p=0.28). There was no significant difference between AYUSH 64 and control group for fever and respiratory symptoms or important lab parameters. No serious adverse event was reported from any group. AYUSH 64 has no significant beneficial effect as compared to control group, this may be because of the less sample size or no actual effect which need to be confirmed by studies with large sample size.

No abstract